BIOMAKERS, a San Francisco-headquartered precision medicine and oncology intelligence company, announced it has closed an additional $8 million in financing as it shifts from building diagnostics and data infrastructure to scaling an AI-native platform designed to support drug and diagnostic development, improve clinical trial execution, and expand access to precision oncology globally. Participants in the round include Labcorp Venture Fund, Oncology Ventures, Endurance28, Zentynel, Sonen Capital, Sky High Fund, and other strategic investors.
The company said it has assembled an integrated oncology ecosystem that combines large-scale molecular diagnostics, longitudinal real-world clinical data, and a diverse, deeply annotated tumor biobank. BIOMAKERS said it operates across more than 20 countries and links genomic data directly to biospecimens and clinical outcomes, creating an intelligence layer intended to help life sciences partners de-risk R&D, broaden trial access, and improve decision-making across the drug development lifecycle.
With its infrastructure in place, BIOMAKERS said it is now focused on platform scalability and monetization, including deploying proprietary AI technologies to structure and harmonize real-world clinical data from hospital electronic medical records. The company said this approach is intended to unlock biological and clinical signals that have historically been difficult to access at scale and position BIOMAKERS as foundational infrastructure for global precision oncology R&D.
In connection with the new phase, BIOMAKERS appointed Ezequiel Renzulli as chief operating officer. Renzulli previously held senior leadership roles at BillionToOne and Tempus, where he worked on scaling AI-driven diagnostics and data platforms for life science partners, according to the company.
BIOMAKERS said its platform includes a tumor biobank of more than 100,000 cases and a growing clinical-genomic dataset representing under-sampled patient populations that are increasingly important for regulatory relevance and therapeutic development. The company added that it maintains direct longitudinal connections to patients, physicians, and healthcare institutions to enable partners to move from data generation to biological insight and clinical execution.
BIOMAKERS said it is headquartered in San Francisco and operates clinical laboratories in Mexico, Brazil, and Argentina, supporting partners across Latin America and the U.S. with access to data and biospecimens at scale.
KEY QUOTES:
“We believed in BIOMAKERS early because the team showed a rare combination of long-term vision and execution in a highly complex market. They’ve demonstrated exceptional discipline in combining science, data, and operations into a scalable platform while remaining focused on long-term value creation.”
Consuelo Valverde, Founder and Managing Partner, Endurance28
“Many companies provide data, but few can link genomic insights directly back to real patient samples at scale. BIOMAKERS has built an end-to-end system that creates durable value for pharma partners while enabling faster, more effective research and development.”
Ben Freeberg, General Partner, Oncology Ventures
“This financing marks a transition from building infrastructure to scaling a global platform. We’ve spent years assembling the data, an integrated diagnostic network, and clinical connectivity required to power precision oncology. Now, with AI at the core of our platform, we’re positioned to make that intelligence broadly accessible, accelerating the development of next-generation therapies and emerging diagnostic tools worldwide.”
Nicolás Kirchuk, Co-Founder and Chief Executive Officer, BIOMAKERS
